BioNTech Reports AHEAD-MERIT Phase 2/3 Clinical Trial Did Not Meet First Dual Primary Endpoint Of Progression-Free Survival For mRNA Cancer Immunotherapy Candidate BNT113 Plus Pembrolizumab Compared With Pembrolizumab Alone

Benzinga

2026.10.13 10:47 (GMT+0)

Apri Benzinga